Cargando…

Prolonged use of bedaquiline in the treatment for MDR-TB in a child

Bedaquiline (Bdq), a novel TB drug, is referred to the most effective drugs and used for the management of multidrug-resistant tuberculosis (MDR-TB). The drug produces a cardiotoxic effect, and its use is limited to six months. We describe a clinical observation of prolonged bedaquiline use in the t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gubkina, Marina F., Khokhlova, Julia Yu., Yukhimenko, Natalia V., Petrakova, Irina Yu.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8551576/ https://www.ncbi.nlm.nih.gov/pubmed/34745886 http://dx.doi.org/10.1016/j.idcr.2021.e01311

Ejemplares similares

Bedaquiline (BDQ) resistance in an adolescent with multidrug-resistant tuberculosis (MDR-TB): An alarm for pediatricians
por: Cesilia, Citra, et al.
Publicado: (2023)

The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens
por: Khan, Uzma, et al.
Publicado: (2019)

Bedaquiline Drug Resistance Emergence Assessment in Multidrug-Resistant Tuberculosis (MDR-TB): a 5-Year Prospective In Vitro Surveillance Study of Bedaquiline and Other Second-Line Drug Susceptibility Testing in MDR-TB Isolates
por: Kaniga, Koné, et al.
Publicado: (2022)

Cost-effectiveness of bedaquiline in MDR and XDR tuberculosis in Italy
por: Codecasa, Luigi R., et al.
Publicado: (2017)

Case Report: Kanamycin Ototoxicity and MDR-TB Treatment Regimen
por: Mantefardo, Bahru, et al.
Publicado: (2021)

‘Z(S)-MDR-TB' versus ‘Z(R)-MDR-TB': improving treatment of MDR-TB by identifying pyrazinamide susceptibility
por: Zhang, Ying, et al.
Publicado: (2012)

Bedaquiline for multidrug-resistant TB in paediatric patients
por: Moodliar, R., et al.
Publicado: (2021)

Addressing bedaquiline treatment interruptions in the treatment of drug-resistant TB
por: Kambili, C., et al.
Publicado: (2022)

Safety of prolonged treatment with bedaquiline in programmatic conditions
por: Zhurkin, Dzmitriy, et al.
Publicado: (2022)

Prolonged use of bedaquiline in two patients with pulmonary extensively drug-resistant tuberculosis: Two case reports
por: Gao, Jing-Tao, et al.
Publicado: (2021)

Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline
por: Villellas, Cristina, et al.
Publicado: (2017)

Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort( )
por: Hewison, Catherine, et al.
Publicado: (2022)

Development of Bedaquiline-Loaded SNEDDS Using Quality by Design (QbD) Approach to Improve Biopharmaceutical Attributes for the Management of Multidrug-Resistant Tuberculosis (MDR-TB)
por: Jahan, Rao Nargis, et al.
Publicado: (2023)

Community-based MDR-TB care project improves treatment initiation in patients diagnosed with MDR-TB in Myanmar
por: Wai, Pyae Phyo, et al.
Publicado: (2018)

Issues in design and interpretation of MDR-TB clinical trials: report of the first Global MDR-TB Clinical Trials Landscape Meeting
por: Mitnick, Carole D, et al.
Publicado: (2015)

Correction to: Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort
Publicado: (2023)

Therapeutic Failure and Acquired Bedaquiline and Delamanid Resistance in Treatment of Drug-Resistant TB
por: Millard, James, et al.
Publicado: (2023)

Six-Month Response to Delamanid Treatment in MDR TB Patients
por: Hewison, Cathy, et al.
Publicado: (2017)

MDR TB Transmission, Singapore
por: Chee, Cynthia B.E., et al.
Publicado: (2013)

Interim Effectiveness and Safety Comparison of Bedaquiline-Containing Regimens for Treatment of Diabetic Versus Non-Diabetic MDR/XDR-TB Patients in China: A Multicenter Retrospective Cohort Study
por: Shi, Li, et al.
Publicado: (2021)

Bedaquiline for multidrug-resistant tuberculosis and QTc prolongation in California
por: Katrak, Shereen, et al.
Publicado: (2021)

Prevalence of pre-extensively drug-resistant tuberculosis (Pre XDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) among extra pulmonary (EP) multidrug resistant tuberculosis (MDR-TB) at a tertiary care center in Mumbai in pre Bedaquiline (BDQ) era
por: Utpat, Ketaki V., et al.
Publicado: (2023)

Pretomanid with bedaquiline and linezolid for drug-resistant TB: a comparison of prospective cohorts
por: Oelofse, S., et al.
Publicado: (2021)

Impact of Rv0678 mutations on patients with drug-resistant TB treated with bedaquiline
por: Kaniga, K., et al.
Publicado: (2022)

Effectiveness of the Novel Anti-TB Bedaquiline against Drug-Resistant TB in Africa: A Systematic Review of the Literature
por: Traoré, Afsatou Ndama, et al.
Publicado: (2022)

Morbidity surveillance and treatment of MDR-TB with the support of NGOs in Ukraine
por: Pozharova, Inga, et al.
Publicado: (2018)

Low-dose amikacin in the treatment of Multidrug-resistant Tuberculosis (MDR-TB)
por: Sabur, Natasha F., et al.
Publicado: (2021)

A rare case of sarcoidosis with necrotizing mediastinal lymphadenitis misdiagnosed as multidrug-resistant tuberculosis (MDR- TB)
por: Prasad, Rajendra, et al.
Publicado: (2022)

Management of MDR-TB: Review of Iran's Experience
por: Masjedi, Mohammad Reza, et al.
Publicado: (2013)

MDR-TB in Pakistan: Challenges, efforts, and recommendations
por: Khan, Mahad Ahmed, et al.
Publicado: (2022)

Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR/MDR/XDR-tuberculosis: a retrospective cohort study in East China
por: Zhang, Shao-Jun, et al.
Publicado: (2022)

MDR M. tuberculosis outbreak clone in Eswatini missed by Xpert has elevated bedaquiline resistance dated to the pre-treatment era
por: Beckert, Patrick, et al.
Publicado: (2020)

Extra-long treatment of MDR-TB osteomyelitis of humerus due to neurotoxicity from the 2nd-line drugs: a case report
por: Naser, Naser, et al.
Publicado: (2023)

Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug
por: Svensson, Elin M., et al.
Publicado: (2015)

Heightened Vulnerability to MDR-TB Epidemics after Controlling Drug-Susceptible TB
por: Bishai, Jason D., et al.
Publicado: (2010)

The incidence of TB and MDR-TB in pediatrics and therapeutic options: a systematic review
por: Harichander, Sheetal, et al.
Publicado: (2022)

Prevalence and Factors Associated with Multidrug-Resistant Tuberculosis (MDR-TB) among Presumptive MDR-TB Patients in Tigray Region, Northern Ethiopia
por: Mehari, Kibriti, et al.
Publicado: (2019)

Cost-effectiveness of new MDR-TB regimens: study protocol for the TB-PRACTECAL economic evaluation substudy
por: Sweeney, Sedona, et al.
Publicado: (2020)

Why has MDR-TB prevalence increased in Iran?
por: Heidary, Mohsen, et al.
Publicado: (2016)

Predictors of Multidrug-Resistant Tuberculosis (MDR-TB) in Sudan
por: Ali, Monadil H., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_d12d117u5aggbks1m4hgv9ehlm